These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Factor SA; Weiner WJ Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289 [TBL] [Abstract][Full Text] [Related]
5. Levodopa treatment of Parkinson's syndrome: past and future. Pletscher A Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486 [No Abstract] [Full Text] [Related]
6. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Reilly DK; Hershey L; Rivera-Calimlim L; Shoulson I Adv Neurol; 1983; 37():51-60. PubMed ID: 6344591 [TBL] [Abstract][Full Text] [Related]
7. A comparative study of bromocriptine and levodopa in Parkinson's disease. Duvoisin RC; Mendoza MM; Yahr MD Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618 [No Abstract] [Full Text] [Related]
8. [Combined therapy of carbidopa and levodopa in Parkinson's disease]. Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908 [No Abstract] [Full Text] [Related]
9. Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa. Bassi S; Albizzati MG; Calloni E; Sbacchi M; Frattola L Br J Clin Pract; 1986 Jul; 40(7):273-5. PubMed ID: 3741741 [No Abstract] [Full Text] [Related]
10. Controversies in the treatment of Parkinson's disease. Friedman J R I Med J (1976); 1985 Oct; 68(10):461-3. PubMed ID: 3865336 [No Abstract] [Full Text] [Related]
11. Controversies in the management of Parkinson's disease. Calne DB; Rinne UK Mov Disord; 1986; 1(3):159-62. PubMed ID: 3143065 [No Abstract] [Full Text] [Related]
12. [Evaluation of combined L-dopa-cyproheptadine therapy of patients with Parkinson's disease]. Fodor M; Solymosi L; Szántó J Orv Hetil; 1980 Jul; 121(27):1631-6. PubMed ID: 7005809 [No Abstract] [Full Text] [Related]
13. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Fermaglich J Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167 [No Abstract] [Full Text] [Related]
14. Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease. Mastrosimone F; Colucci d'Amato C; De Angelis G; Iaccarino C; Giordano L; Marmo E J Med; 1980; 11(5-6):377-83. PubMed ID: 6962824 [No Abstract] [Full Text] [Related]
15. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease A short commentary. Quinn NP J Neurol; 2003 Jan; 250(1):97. PubMed ID: 12528000 [No Abstract] [Full Text] [Related]
19. An open trial of high-dosage antioxidants in early Parkinson's disease. Fahn S Am J Clin Nutr; 1991 Jan; 53(1 Suppl):380S-382S. PubMed ID: 1985415 [TBL] [Abstract][Full Text] [Related]
20. Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]